Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy

The goal of this clinical trial is to learn if Naderin works to prevent low white blood cell counts in people with breast cancer receiving first-line chemotherapy. The main questions it aims to answer are: 1. Does taking Naderin lower the number of people who get low white blood cell counts during chemotherapy? 2. Does taking Naderin help people finish all of their chemotherapy treatments without interruptions? Researchers will compare people who receive chemotherapy with Naderin to people who receive chemotherapy alone to see if Naderin helps prevent low white blood cell counts. Participants will: Receive standard AC chemotherapy for breast cancer Either receive Naderin along with chemotherapy or receive chemotherapy alone Have regular blood tests to check white blood cell counts Complete all 4 chemotherapy cycles Key finding: The study found that 14 out of 100 people who received Naderin developed low white blood cell counts, compared to 39 out of 100 people who did not receive Naderin.

NCT Number	NCT07671547
Lead Sponsor	MIPO Clinic Collaborators: Asfendiyarov Kazakh National Medical University
Conditions	Breast Cancer, Hematologic Disorder, Leukopenia, Chemotherapy-Induced Myelosuppression
Enrollment	79 participants
Start Date	2014-01-01
Primary Completion	2015-12-31 (estimated)
Study Completion	2016-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-30